Skip to main content
Carisma Therapeutics Inc. logo

Carisma Therapeutics Inc. — Investor Relations & Filings

Ticker · CARM ISIN · US14216R1014 LEI · 549300DGKHONOZQIY116 US Manufacturing
Filings indexed 853 across all filing types
Latest filing 2024-02-02 Director's Dealing
Country US United States of America
Listing US CARM

About Carisma Therapeutics Inc.

https://sesenbio.com/

Carisma Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of engineered macrophage-based therapeutics. The company's proprietary cell therapy platform is centered on Chimeric Antigen Receptor Macrophages (CAR-M) and CAR-Monocytes. This approach is designed to leverage the unique abilities of macrophages to infiltrate solid tumors, overcome the immunosuppressive tumor microenvironment, and stimulate a broad anti-tumor response. Carisma's pipeline is focused on developing treatments for cancer and other serious disorders, including fibrosis.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2024-02-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-02-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-02-02 English
SC 13G/A
Major Shareholding Notification
2024-02-02 English
SC 13D/A
Major Shareholding Notification
2024-01-26 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.